Prognostic significance of molecular classification of breast invasive ductal carcinoma

Archives of Gynecology and Obstetrics

Volumn 280, Issue 1, 2009, Pages 43-48

  Muñoz, Mar ^a   Fernández Aceñero, M Jesús ^b   Martín, Silvia ^a   Schneider, José ^c  

^a Parla Hospital   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Invasive ductal carcinoma; Molecular classification; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; RECURRENCE RISK; ANALYSIS OF VARIANCE; BREAST TUMOR; CHI SQUARE DISTRIBUTION; CLASSIFICATION; DISEASE FREE SURVIVAL; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 67649637545     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-008-0867-1     Document Type: Article

References (14)

1. C Smigal A Jemal E Ward V Cokkinides R Smith HL Howe M Thun 2006 Trends in breast cancer by race and ethnicity: update 2006 CA Cancer J Clin 56 168 183 (Pubitemid 43847927)
2. R Nishimura Y Okumura N Arima 2008 Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival Breast Cancer 15 57 64 10.1007/s12282-007-0014-z
3. IN Olver 2008 Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when Future Oncol 4 125 131 10.2217/14796694.4.1.125
4. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenchikov C Williams SX Zhu PE Lonning AL Borresen PO Brown D Botstein 2000 Molecular portraits of human tumours Nature 406 747 752 10.1038/35021093
5. LJ Van't Veer H Dai MJ van de Vijver YD He AA Hart M Mao HL Meterse K van der Kooy MJ Marton AT Witteveeen GJ Schreiber RM Kerkhoven C Roberts 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 530 536 10.1038/415530a
6. J Schneider A Tejerina Gómez J Sánchez C Perea A Tejerina Bernal AR Lucas 2007 Molecular subgroups of small (pT1) breast carcinomas belonging exclusively to the ductal infiltrating variety Cancer Genomics Proteomics 4 399 402
7. MJ Fdez-Aceñero J Fariña M Galindo P Aragoncillo 1998 Vascular enumeration as a significant prognosticator for invasive breast carcinoma J Clin Oncol 16 1684 1688
8. J Finetti N Cervera E Charafe C Chabannon C Charpin M Chaffanet J Jacquemier P Viens D Birnbaum F Bertucci 2008 Sixteen kinase gene expression identifies luminal breast cancer with poor prognosis Cancer Res 68 767 776 10.1158/0008-5472.CAN-07-5516
9. NS Goldstein D Decker D Severson S Schell F Vicini J Margolis NS Dekhne 2007 Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy Cancer 110 1687 1696 10.1002/cncr.22981
10. P Tang P Wang P Bourne 2008 Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol 39 506 513 10.1016/j.humpath.2007.09.005
11. EA Rakha ME El-Sayed AR Green AHS Lee JF Robertson IO Ellis 2007 Prognostic markers in triple negative breast cancer Cancer 109 25 32 10.1002/cncr.22381
12. C Lohrisch M Piccart 2001 Her2/neu as a predictive factor in breast cancer Clin Breast Cancer 2 129 135 10.3816/CBC.2001.n.017 (Pubitemid 32771564)
13. W Reed E Hannisdal PJ Boehler S Gundersen H Host J Marthin 2000 The prognostic value of p53 and c-erbB2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factor in 613 patients with a follow up of 14-30 years Cancer 88 804 813 10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y
14. M van de Rijn CM Perou R Tibshirani P Haas O Kallioniemi J Kononen J Torhorst G Sauter M Zuber OR Köchli F Mross H Dieterich R Seitz D Ross D Botstein P Brown 2002 Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome Am J Pathol 161 1991 1996 (Pubitemid 35434844)